DECO

A randomised phase II trial of weekly docetaxel (Taxotere®) chemoradiotherapy +/- cetuximab (Erbitux®) in the treatment of localised resectable cancer of the oesophagus.

Share

Trial Status

Completed

Cancer Type

Oesophageal Cancer

Aim

Although patients with localised oesophageal cancer may have their cancer fully removed by surgery, it often comes back. Chemotherapy given after surgery has, in general, not improved outcomes compared to surgery alone. A combination of chemotherapy and radiotherapy given before surgery might help, but standard treatment has not yet been defined. This trial, which has been developed and is being led by AGITG investigators, tests a novel combination of chemotherapy and radiotherapy, with and without a new type of antibody treatment given before surgery. Patients are randomly split into two groups: one group receives chemotherapy and radiotherapy; and the other receives the same treatment plus the new antibody treatment. Investigators will assess the amount of tumour left at the time of surgery, the length of time before the tumour begins to grow again, and length of life in the two groups.

Summary

AGITG felt it would be appropriate to close the DECO study because accural targets were not going to be met. The study was officially closed to recruitment on 9 December 2009.

Trial Status

Completed

Cancer Type

Oesophageal Cancer

Aim

Although patients with localised oesophageal cancer may have their cancer fully removed by surgery, it often comes back. Chemotherapy given after surgery has, in general, not improved outcomes compared to surgery alone. A combination of chemotherapy and radiotherapy given before surgery might help, but standard treatment has not yet been defined. This trial, which has been developed and is being led by AGITG investigators, tests a novel combination of chemotherapy and radiotherapy, with and without a new type of antibody treatment given before surgery. Patients are randomly split into two groups: one group receives chemotherapy and radiotherapy; and the other receives the same treatment plus the new antibody treatment. Investigators will assess the amount of tumour left at the time of surgery, the length of time before the tumour begins to grow again, and length of life in the two groups.

Summary

AGITG felt it would be appropriate to close the DECO study because accural targets were not going to be met. The study was officially closed to recruitment on 9 December 2009.

Principal Investigator

Dr Michael Michael

Funding

Merck Serono Australia Pty Limited , Sanofi-Aventis Group Pty Limited (Australia)